Today, Synaps is supported by different partners involving Clinical, Academic and SMEs groups. Together, basic scientists, neurosurgeons, SMEs are building capacities to develop a new treatment modality for GBM relying on 5-aminolevulinic acid (5-ALA).
Synaps proposes a seamless treatment strategy based on intraoperative photodynamic therapy (PDT) to improve local control, and fully embeddable into the current standard of care. SYNAPS is coordinated by University of Lille - ONCO-Thai lab and gathers partners with large experience in i) clinical trial design (IDDI has provided biostatistical and data-management services for 340 clinical trials over the past 5 years, ECRIN is the dedicated European Infrastructure), ii) in rare diseases drug development (OP2 has been managing several clinical trials in rare disorders including a phase 3 trial with 10 centres in the EU and the US), iii) in medical device (INTERMEDIC has developed a dedicated LASER technology for a phase 3 clinical trial on vascular-targeted PDT) iv) "omics" (Oncoradiomics and LEITAT). The involvement of Clinical teams (University Hospital of Lille, ULB-ERASME, Medical University of Gräz) in large-scale clinical trials on new GBM treatments is of importance to ensure the success in evaluating this new treatment.
